Journals / Zeynep Kamil Tıp Bülteni / 2015 / Cilt: 46 - Sayı: 4

Immunohistochemical evaluation of C-KIT expression in uterine carcinosarcomas

Uterin karsinosarkomlarda immunohistokimyasal olarak C-KIT ekspresyonunun değerlendirilmesi

Pages
93–97
Publication Date
2016-01-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies of c-kit expression in larger series of carcinosarcomas must be studied in order to clarify the controversial issues.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Carcinosarcoma is a very aggressive neoplasm.
📊
Key Findings & Data:Consequently, c-kit expression may have significant clinical implications for this tumor.
💡
Conclusion & Impact:Further studies of c-kit expression in larger series of carcinosarcomas must be studied in order to clarify the controversial issues.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:uterus · karsinosarkom · c-kit

Abstract

Objective: Carcinosarcoma is a very aggressive neoplasm. The use of tyrosine kinase inhibitors has resulted in successful treatment of KIT-positive neoplasms. Consequently, c-kit expression may have significant clinical implications for this tumor. The purpose of the present study was to assess c-kit expression in the carcinomatous and sarcomatous component of carcinosarcoma and to identify if KIT represents a therapeutic target for treatment of this neoplasm.Material and Method: Immunohistochemical staining for c-kit was performed on paraffin-embedded tissue blocks of 20 uterine specimens with carcinosarcoma.Results: In the stromal component of carcinosarcoma, no immunohistochemically c-kit stained cells were observed and in the epithelial component, c-kit staining was present in 9 cases.Conclusion: The results seem to suggest that c-kit probably plays no major role in the carcinogenesis of the majority of these tumors. Further studies of c-kit expression in larger series of carcinosarcomas must be studied in order to clarify the controversial issues.

Özet

Amaç: Karsinosarkom oldukça agresif bir neoplazmdır. KIT-pozitif neoplazmlarda tirozin kinaz inhibitörleri tedavide başarılı sonuçlar vermektedir. Bu nedenle, bu tümörlerde c-kit ekspresyonu klinik açıdan önemli olabilir. Bu çalışmanın amacı, karsinosarkomun karsinomatöz ve sarkomatöz komponenetlerinde c-kit ekspresyonunu incelemek ve bu neoplazmlarda KIT’in terapötik bir hedef olarak kullanılabilirliğini saptamaktır.Gereç ve Yöntem: Karsinosarkom tanısı almış 20 uterusa ait parafine gömülü bloklara immunohistokimyasal olarak c-kit boyaması uygulandı.Bulgular: Karsinosarkomların stromal komponentlerinde immunohistakimyasal olarak c-kit boyanan hücre saptanmadı, ve epitelyal komponenette ise 9 olguda c-kit boyaması mevcuttu.Sonuç: Sonuçlar c-kit’in bu tümörlerin karsinogenezinde muhtemelen major bir rol oynamadığını destekler görünmektedir. Tartışmalı konuları açıklığa kavuşturmak için geniş serilerle yapılacak c-kit ekspresyonunu belirleyecek yeni çalışmalar gerekmektedir.

🔖

Cite This Article

KAYGUSUZ, E. I. (2016). Immunohistochemical evaluation of C-KIT expression in uterine carcinosarcomas. Zeynep Kamil Tıp Bülteni, Cilt: 46 - Sayı: 4, 93–97. https://ajindex.com/articles/725493

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, et al. Human proto-oncogene kit, a new cell surface-receptor tyrosine kinase for unidentified ligand. EMBO J 1987;6:3341 – 51. Williams DE, Eisenman J, Baird A, Rauch C, Van Ness K, March CJ, et al. Identification of a ligand for the c-kit proto-oncogene. Cell 1990;63:167 – 74. d’Auriol L, Mattei MG, Andre C, Galibert F. Localization of the human c-kit protooncogene on the q11–q12 region of chromosome 4. Hum Genet 1988;78:374 – 6. Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K, et al. C-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 1995;91:6610 – 30. Dudani S, Kalhan S, Sharma S, Gupta A. Gastrointestinal stromal tumours (GIST)-pathology and clinical applications of recent molecular advences-A perspective review. Çağdaş Tıp Dergisi 2014;4:85-90.
  2. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, et al. KIT activation is a ubiquitous feature of gastrointestinal stroma. Cancer Res 2001;61(22):8118 – 21. Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinibe mesylate (STI571) Eur J Cancer 2002;38 (Suppl 5):52–59.
  3. Druker BJ, Sawyers CL., Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 2001;344:1038–42. DeMatteo RP. The GIST of targeted cancer therapy: a tumor gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular nhibitor (STI571) Ann Surg Oncol 2002;9:831–3. Demetri GD. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 2001;28 (Suppl 17):19–26.
  4. Heinrich MC., Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484–95.
  5. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to treatment of KIT-positive malignancies J Clin Oncol 2002;20:1692–703.
  6. Elmore LW, Domson K, Moore JR, Kornstein M, Burks RT. Expression of c-kit (CD117) in benign and malignant human endometrial epithelium. Arch Pathol Lab Med 2001;125:146–51.
  7. Scobie JV, Acs G, Bandera CA, Blank SV, Wheeler JE, Pasha TL, et al. C-kit immun